US Rheumatologists Show Continued Uptake of Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis, Though Safety Concerns and Lack of Experience in the Market Withhold Full Potential

[In The News]

EXTON, Pa., March 25, 2019 /PRNewswire/ -- Overall brand share among biologic/JAK-treated patients in the US rheumatoid arthritis (RA) market has remained relatively stagnant over the past year, according to Spherix Global Insights' latest quarterly wave of RealTime Dynamix™: Rheumatoid...

View the full article